glucagon-like peptide-1 (GLP-1) Archive — Page 3 of 3

July 12, 2018

Team explores diabetes drug’s ability to treat RSV infection

A drug used to treat diabetes may point to new therapies for respiratory syncytial virus (RSV) bronchiolitis — inflammation and obstruction of the lungs’ small airways. A multi-disciplinary team of Vanderbilt investigators has demonstrated that liraglutide reduces the inflammatory response to RSV infection in a mouse model of the disease.

By Leigh MacMillan

September 21, 2017

Pancreatic islets study may spur diabetes treatment advances

Investigators in the Vanderbilt Diabetes Research and Training Center (VDRTC) and collaborators at Stanford University have discovered new insights into the molecular mechanisms of cell proliferation in juvenile human pancreatic islets, information that could lead to new treatments for diabetes.

By Jill Clendening

June 22, 2017

Vanderbilt Pre-Diabetes Clinic tackles type 2 diabetes in children

In Middle Tennessee, where roughly one-third of children are overweight or obese, the risk of developing pediatric type 2 diabetes is high and the consequences can be serious.

By Meredith Jackson

March 16, 2017

VUMC joins cutting-edge obesity research network

Vanderbilt University Medical Center (VUMC) is one of four centers receiving a $15 million, four-year research award from the American Heart Association (AHA) to provide cutting-edge research on obesity as part of its sixth Strategically Focused Research Network (SFRN).

By Craig Boerner

July 18, 2016

Diabetes drugs may ease addiction

Drugs that are being used clinically to treat obesity and diabetes may also have a role in treating drug abuse.

By Bill Snyder

January 28, 2016

Award recognizes Niswender’s research achievements

Kevin Niswender, M.D., Ph.D., a physician-scientist at Vanderbilt University Medical Center whose work has helped advance understanding of diseases ranging from obesity to schizophrenia, is one of 10 recipients of the 2016 Harrington Scholar-Innovator Awards.